Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

ACROBiosystemsSupplier Diversity Partner Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128)  DFS Item

Manufacturer:  ACROBiosystemsSupplier Diversity Partner SPDM128100UG

Antibody;100UG;Human IgG1/kappa;This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is deteced with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.;Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (SPD-M128) is a chimeric monoclonal antibody combining the constant domains of the human IgG1 molecule with mouse variable regions. Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.;This protein . ;Immobilized SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H1) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM128) (Cat. No. SPD-M128) with a linear range of 0.2-1.5ng/mL (QC tested).;Serial dilutions of Anti-SARS-CoV-2 RBD Potent Neutralizing Antibody, Chimeric mAb, Human

Catalog No. 50-205-5036

Add to cart

Provide Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Cancel Submit